Format

Send to

Choose Destination
Multidiscip Respir Med. 2014 Oct 15;9(1):50. doi: 10.1186/2049-6958-9-50. eCollection 2014.

COPD: maximization of bronchodilation.

Author information

1
Pulmonary and TB Unit, Vittorio Veneto General Hospital, Vittorio Veneto, TV Italy.
2
Department of Experimental and Clinical Medicine, Section of Respiratory Medicine, AOU Careggi, Florence, Italy.
3
Pneumotisiology, NiguardaCa'Granda Hospital, Milan, Italy.
4
Department of Medical and Surgical Sciences, Section of Respiratory Diseases, University "Magna Graecia" of Catanzaro, Catanzaro, Italy.
5
Pneumology Rehabilitation, Villa delle Querce Hospital, Nemi, Rome, Italy.
6
Department of Internal Medicine and Medical Specialities, Respiratory Diseases and Allergology, Università degli Studi di Genova, Genoa, Italy.
7
Pneumology Unit, C. e G. Mazzoni Hospital, Ascoli Piceno, Italy.
8
Department of Pneumology, San Gerardo Hospital Monza (Mi), Monza, Italy.
9
Pneumology Unit, AO S.Camillo-Forlanini, Rome, Italy.
10
Department of Medicine and Surgery, University of Salerno, Salerno, Italy.

Abstract

The most recent guidelines define COPD in a multidimensional way, nevertheless the diagnosis is still linked to the limitation of airflow, usually measured by the reduction in the FEV1/FVC ratio below 70%. However, the severity of obstruction is not directly correlated to symptoms or to invalidity determined by COPD. Thus, besides respiratory function, COPD should be evaluated based on symptoms, frequency and severity of exacerbations, patient's functional status and health related quality of life (HRQoL). Therapy is mainly aimed at increasing exercise tolerance and reducing dyspnea, with improvement of daily activities and HRQoL. This can be accomplished by a drug-induced reduction of pulmonary hyperinflation and exacerbations frequency and severity. All guidelines recommend bronchodilators as baseline therapy for all stages of COPD, and long-acting inhaled bronchodilators, both beta-2 agonist (LABA) and antimuscarinic (LAMA) drugs, are the most effective in regular treatment in the clinically stable phase. The effectiveness of bronchodilators should be evaluated in terms of functional (relief of bronchial obstruction and pulmonary hyperinflation), symptomatic (exercise tolerance and HRQoL), and clinical improvement (reduction in number or severity of exacerbations), while the absence of a spirometric response is not a reason for interrupting treatment, if there is subjective improvement in symptoms. Because LABA and LAMA act via different mechanisms of action, when administered in combination they can exert additional effects, thus optimizing (i.e. maximizing) sustained bronchodilation in COPD patients with severe airflow limitation, who cannot benefit (or can get only partial benefit) by therapy with a single bronchodilator. Recently, a fixed combination of ultra LABA/LAMA (indacaterol/glycopyrronium) has shown that it is possible to get a stable and persistent bronchodilation, which can help in avoiding undesirable fluctuations of bronchial calibre.

KEYWORDS:

Bronchodilation; COPD; Dyspnea; Exercise tolerance; Fixed combination indacaterol/glycopyrronium; HRQoL; Hyperinflation; LABA; LAMA

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center